Telavant: Roche to buy autoimmune drugmaker from Pfizer, Roivant for $7B

Roche has agreed to acquire Telavant Holdings - the maker of an inflammatory bowel disease drug - from Roivant Sciences and Pfizer for $7.25 billion, the Switzerland-based company said in an Oct. 23 news release.